gptkbp:instance_of
|
gptkb:pharmaceuticals
|
gptkbp:administered_by
|
oral tablet
|
gptkbp:approves
|
gptkb:1996
gptkb:European_Union
gptkb:United_States
|
gptkbp:atccode
|
N06 DA02
|
gptkbp:available_as_generic
|
gptkb:Yes
|
gptkbp:brand
|
gptkb:Aricept
|
gptkbp:casnumber
|
120014-06-4
|
gptkbp:category
|
gptkb:C
|
gptkbp:chemical_formula
|
C24 H29 NO3
|
gptkbp:class
|
Cognitive enhancer
|
gptkbp:clinical_trial
|
Phase III
|
gptkbp:composed_by
|
gptkb:chemical_compound
|
gptkbp:contraindication
|
severe liver disease
severe lung disease
allergy to donepezil
|
gptkbp:developed_by
|
gptkb:Pfizer
gptkb:Eisai
|
gptkbp:dosage_form
|
5 mg tablet
10 mg tablet
23 mg tablet
|
gptkbp:first_synthesis_year
|
gptkb:1983
|
https://www.w3.org/2000/01/rdf-schema#label
|
donepezil
|
gptkbp:impact_on_behavior
|
reduces behavioral symptoms
|
gptkbp:impact_on_cognition
|
improves cognitive function
|
gptkbp:impact_on_daily_living
|
improves daily living activities
|
gptkbp:interacts_with
|
NSAIDs
beta-blockers
anticholinergic drugs
certain antidepressants
|
gptkbp:is_monitored_by
|
monitor for side effects
regular cognitive assessments
|
gptkbp:legal_status
|
Prescription only
|
gptkbp:lifespan
|
70 hours
|
gptkbp:long_term_use_effect
|
tolerance may develop
|
gptkbp:marketed_as
|
gptkb:Aricept
|
gptkbp:mechanism_of_action
|
acetylcholinesterase inhibitor
|
gptkbp:metabolism
|
liver
|
gptkbp:patent_expiration_year
|
gptkb:2010
|
gptkbp:research_focus
|
gptkb:neurodegenerative_diseases
Alzheimer's disease treatment
dementia treatment
|
gptkbp:rounds
|
urine
feces
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
insomnia
muscle cramps
|
gptkbp:symptoms
|
none reported
|
gptkbp:used_for
|
gptkb:neurodegenerative_diseases
|
gptkbp:weight
|
379.49 g/mol
|
gptkbp:bfsParent
|
gptkb:Aricept
|
gptkbp:bfsLayer
|
6
|